Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to anti-TNFα therapy in a United Kingdom (UK) and Republic of Ireland) specific population.
Epistemonikos ID: 362b234fa5748cbcd47a315494a4190bfce31346
First added on: May 11, 2024